In Brief: Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pacemakers, Inc.: Guidant unit receives FDA approval for its Ventak P3 automatic implantable cardioverter defibrillator. The P3 is a shock-only version of the company's Ventak PRxIII tiered-therapy defibrillator, which received FDA's nod in May ("The Gray Sheet" May 8, In Brief). Guidant says the P3 offers the same therapy features as its earlier-version Ventak P2 shock-only device, but is 30% smaller in size...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.